|
Video: What is a Stock Split?
|
|
iTeos Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of a differentiated immuno-oncology therapeutics for patients. Co.'s product candidate, inupadenant, is designed as a selective small molecule antagonist of the adenosine A2a receptor, in the adenosine pathway, a main driver of immunosuppression in the tumor microenvironment across a range of tumors. Co.'s main antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains, an immune checkpoint with multiple mechanisms of action leading to immunosuppression. According to our ITOS split history records, iTeos Therapeutics has had 0 splits. | |
|
iTeos Therapeutics (ITOS) has 0 splits in our ITOS split history database.
Looking at the ITOS split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into iTeos Therapeutics shares, starting with a $10,000 purchase of ITOS, presented on a split-history-adjusted basis factoring in the complete ITOS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/27/2020 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$17.57 |
|
End price/share: |
$13.64 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-22.37% |
|
Average Annual Total Return: |
-6.66% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$7,764.47 |
|
Years: |
3.67 |
|
|
|
|
|